logo
Plus   Neg
Share
Email
Comment

Fossil Q1 Profit Grows - Quick Facts

Fossil Inc.'s (FOSL) first-quarter net income attributable to the company increased to $58.14 million or $0.93 per share from $55.82 million or $0.86 per share last year. On average, 15 analysts polled by Thomson Reuters expected earnings per share of $0.92 for the quarter. Analysts' estimates typically exclude one-time items.

The company said the recent quarter's results included a $0.03 per share rise related to net foreign currency exchange gains in comparison to the prior fiscal year first quarter and a $0.03 per share increase related to a 3.7% lower outstanding share count as a result of the company's ongoing buyback program.

Net sales increased 9.8% to $589.5 million from $537.0 million in the earlier year quarter, and up 11.1% in constant dollars. Thirteen analysts estimated revenues of $617.64 million for the quarter.

For the second quarter of fiscal 2012, the company sees reported net sales to increase about 16% with constant dollar net sales increasing 19%. Including Skagen activities, second quarter 2012 earnings per share are expected to be in a range of $0.77 - $0.79. Analysts expect earnings of $0.94 per share for the second quarter.

For fiscal 2012, the company currently projects reported net sales to increase around 16% with constant dollar net sales increasing nearly 18%. Net sales of Skagen, included in this estimate, are expected to benefit overall sales growth by 5%. Full-year earnings per share are now estimated to be in a range of $5.30 - $5.40, while 15 analysts project 2012 earnings of $5.56 per share.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Opera, a web browser for Windows, macOS, and Linux operating systems, has added cryptocurrency mining protection to its mobile browsers. It is part of the browser's ad blocker function. In its desktop-based versions, Opera had introduced cryptocurrency miner protection in early January. French drug giant Sanofi SA Monday announced an agreement to buy US-based hemophilia drugmaker Bioverativ Inc. (BIVV) for around $11.6 billion. The deal expands Sanofi's presence in specialty care and strengthens leadership in rare diseases. Sanofi shares were losing around 4 percent in the early morning trading in Paris. Swiss banking giant UBS Group AG reported Monday a hefty net loss in its fourth quarter hurt by a charge related to US tax law changes. Pre-tax profit, however, increased from last year with improved operating income and lower expenses. Further, the company announced an increase in dividend, as well as a share buyback of up to 2 billion Swiss francs.
comments powered by Disqus
Follow RTT